http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 12 Jun 2026 04:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Autolus+Therapeutics+Receives+Prix+Galien+UK+Award/26637543.html <p align="justify">LONDON and GAITHERSBURG, Md., June 12, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced that the Galien Foundation has presented the Company with the 2026 Prix Galien UK Award for Best Biotechnology Product. Winners of the prestigious Prix Galien awards are selected by a UK Awards Committee, which comprises 12 experts in the field who are leaders in UK healthcare. </p> <p align="justify">“We are honored to receive this recognition from Prix Galien UK. Autolus was founded, in collaboration with http://www.streetinsider.com/Press+Releases/Autolus+Therapeutics+Receives+Prix+Galien+UK+Award/26637543.html Fri, 12 Jun 2026 04:00:00 -0400 AUTL AUTL http://www.streetinsider.com/Press+Releases/Autolus+Therapeutics+Receives+Prix+Galien+UK+Award/26637543.html <p align="justify">LONDON and GAITHERSBURG, Md., June 12, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced that the Galien Foundation has presented the Company with the 2026 Prix Galien UK Award for Best Biotechnology Product. Winners of the prestigious Prix Galien awards are selected by a UK Awards Committee, which comprises 12 experts in the field who are leaders in UK healthcare. </p> <p align="justify">“We are honored to receive this recognition from Prix Galien UK. Autolus was founded, in collaboration with http://www.streetinsider.com/Press+Releases/Autolus+Therapeutics+Receives+Prix+Galien+UK+Award/26637543.html Fri, 12 Jun 2026 04:00:00 -0400 AUTL AUTL http://www.streetinsider.com/Globe+Newswire/Autolus+Therapeutics+Receives+Prix+Galien+UK+Award/26637543.html <p align="justify">LONDON and GAITHERSBURG, Md., June 12, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced that the Galien Foundation has presented the Company with the 2026 Prix Galien UK Award for Best Biotechnology Product. Winners of the prestigious Prix Galien awards are selected by a UK Awards Committee, which comprises 12 experts in the field who are leaders in UK healthcare. </p> <p align="justify">“We are honored to receive this recognition from Prix Galien UK. Autolus was founded, in collaboration with http://www.streetinsider.com/Globe+Newswire/Autolus+Therapeutics+Receives+Prix+Galien+UK+Award/26637543.html Fri, 12 Jun 2026 04:00:00 -0400 AUTL AUTL http://www.streetinsider.com/Globe+Newswire/Autolus+Therapeutics+Receives+Prix+Galien+UK+Award/26637543.html <p align="justify">LONDON and GAITHERSBURG, Md., June 12, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced that the Galien Foundation has presented the Company with the 2026 Prix Galien UK Award for Best Biotechnology Product. Winners of the prestigious Prix Galien awards are selected by a UK Awards Committee, which comprises 12 experts in the field who are leaders in UK healthcare. </p> <p align="justify">“We are honored to receive this recognition from Prix Galien UK. Autolus was founded, in collaboration with http://www.streetinsider.com/Globe+Newswire/Autolus+Therapeutics+Receives+Prix+Galien+UK+Award/26637543.html Fri, 12 Jun 2026 04:00:00 -0400 AUTL AUTL http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Autolus+Therapeutics++++++For%3A+Jun+05/26620286.html si-local-file:///var/storage/secattach/20260609/26620286.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Autolus+Therapeutics++++++For%3A+Jun+05/26620286.html Tue, 09 Jun 2026 07:31:00 -0400 AUTL O.37399203 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Autolus+Therapeutics++++++For%3A+Jun+05/26620286.html si-local-file:///var/storage/secattach/20260609/26620286.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Autolus+Therapeutics++++++For%3A+Jun+05/26620286.html Tue, 09 Jun 2026 07:31:00 -0400 AUTL O.37399203 http://www.streetinsider.com/Press+Releases/Autolus+Therapeutics+to+Participate+in+Upcoming+Investor+Conferences/26553237.html <p align="justify">LONDON and GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the Company will present and host meetings at two upcoming investor conferences.</p> <p><strong>William Blair’s 46th Annual Growth Stock Conference</strong><br />Date and time: June 2, 2026; 1:20pm CDT / 7:20pm BST<br />Location: Chicago, IL<br />Presenter: Chief Executive Officer Dr. Christian Itin</p> <p align="justify"><strong>Jefferies Global Healthcare Conference</strong><br />Date and time: June 3, 2026; 10:30am EDT / 3:30pm BST<br />Location: New York, NY<br />Presenter: Chief Executive Officer Dr. Christian http://www.streetinsider.com/Press+Releases/Autolus+Therapeutics+to+Participate+in+Upcoming+Investor+Conferences/26553237.html Wed, 27 May 2026 07:00:00 -0400 AUTL AUTL http://www.streetinsider.com/Press+Releases/Autolus+Therapeutics+to+Participate+in+Upcoming+Investor+Conferences/26553237.html <p align="justify">LONDON and GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the Company will present and host meetings at two upcoming investor conferences.</p> <p><strong>William Blair’s 46th Annual Growth Stock Conference</strong><br />Date and time: June 2, 2026; 1:20pm CDT / 7:20pm BST<br />Location: Chicago, IL<br />Presenter: Chief Executive Officer Dr. Christian Itin</p> <p align="justify"><strong>Jefferies Global Healthcare Conference</strong><br />Date and time: June 3, 2026; 10:30am EDT / 3:30pm BST<br />Location: New York, NY<br />Presenter: Chief Executive Officer Dr. Christian http://www.streetinsider.com/Press+Releases/Autolus+Therapeutics+to+Participate+in+Upcoming+Investor+Conferences/26553237.html Wed, 27 May 2026 07:00:00 -0400 AUTL AUTL http://www.streetinsider.com/Globe+Newswire/Autolus+Therapeutics+to+Participate+in+Upcoming+Investor+Conferences/26553237.html <p align="justify">LONDON and GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the Company will present and host meetings at two upcoming investor conferences.</p> <p><strong>William Blair’s 46th Annual Growth Stock Conference</strong><br />Date and time: June 2, 2026; 1:20pm CDT / 7:20pm BST<br />Location: Chicago, IL<br />Presenter: Chief Executive Officer Dr. Christian Itin</p> <p align="justify"><strong>Jefferies Global Healthcare Conference</strong><br />Date and time: June 3, 2026; 10:30am EDT / 3:30pm BST<br />Location: New York, NY<br />Presenter: Chief Executive Officer Dr. Christian http://www.streetinsider.com/Globe+Newswire/Autolus+Therapeutics+to+Participate+in+Upcoming+Investor+Conferences/26553237.html Wed, 27 May 2026 07:00:00 -0400 AUTL AUTL http://www.streetinsider.com/Globe+Newswire/Autolus+Therapeutics+to+Participate+in+Upcoming+Investor+Conferences/26553237.html <p align="justify">LONDON and GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the Company will present and host meetings at two upcoming investor conferences.</p> <p><strong>William Blair’s 46th Annual Growth Stock Conference</strong><br />Date and time: June 2, 2026; 1:20pm CDT / 7:20pm BST<br />Location: Chicago, IL<br />Presenter: Chief Executive Officer Dr. Christian Itin</p> <p align="justify"><strong>Jefferies Global Healthcare Conference</strong><br />Date and time: June 3, 2026; 10:30am EDT / 3:30pm BST<br />Location: New York, NY<br />Presenter: Chief Executive Officer Dr. Christian http://www.streetinsider.com/Globe+Newswire/Autolus+Therapeutics+to+Participate+in+Upcoming+Investor+Conferences/26553237.html Wed, 27 May 2026 07:00:00 -0400 AUTL AUTL http://www.streetinsider.com/Press+Releases/Autolus+Therapeutics+to+Present+Clinical+Data+Update+at+the+American+Society+of+Clinical+Oncology+Annual+Meeting+2026/26536774.html <p align="justify">LONDON and GAITHERSBURG, Md., May 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, announces the online publication of an abstract submitted to the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago, Illinois.</p> <p align="justify">“Data to be presented at the upcoming ASCO Annual Meeting provides insight into the use of obe-cel in patients with B-ALL and extramedullary disease (EMD), which is typically associated with shorter median and long-term survival http://www.streetinsider.com/Press+Releases/Autolus+Therapeutics+to+Present+Clinical+Data+Update+at+the+American+Society+of+Clinical+Oncology+Annual+Meeting+2026/26536774.html Thu, 21 May 2026 17:10:00 -0400 A.31293549 A.32727947 A.50216726 AUTL O.00048394 O.00573636 O.21612337 O.37399203 http://www.streetinsider.com/Press+Releases/Autolus+Therapeutics+to+Present+Clinical+Data+Update+at+the+American+Society+of+Clinical+Oncology+Annual+Meeting+2026/26536774.html <p align="justify">LONDON and GAITHERSBURG, Md., May 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, announces the online publication of an abstract submitted to the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago, Illinois.</p> <p align="justify">“Data to be presented at the upcoming ASCO Annual Meeting provides insight into the use of obe-cel in patients with B-ALL and extramedullary disease (EMD), which is typically associated with shorter median and long-term survival http://www.streetinsider.com/Press+Releases/Autolus+Therapeutics+to+Present+Clinical+Data+Update+at+the+American+Society+of+Clinical+Oncology+Annual+Meeting+2026/26536774.html Thu, 21 May 2026 17:10:00 -0400 A.31293549 A.32727947 A.50216726 AUTL O.00048394 O.00573636 O.21612337 O.37399203 http://www.streetinsider.com/Press+Releases/Autolus+Therapeutics+to+Present+Clinical+Data+Update+at+the+American+Society+of+Clinical+Oncology+Annual+Meeting+2026/26536774.html <p align="justify">LONDON and GAITHERSBURG, Md., May 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, announces the online publication of an abstract submitted to the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago, Illinois.</p> <p align="justify">“Data to be presented at the upcoming ASCO Annual Meeting provides insight into the use of obe-cel in patients with B-ALL and extramedullary disease (EMD), which is typically associated with shorter median and long-term survival http://www.streetinsider.com/Press+Releases/Autolus+Therapeutics+to+Present+Clinical+Data+Update+at+the+American+Society+of+Clinical+Oncology+Annual+Meeting+2026/26536774.html Thu, 21 May 2026 17:10:00 -0400 A.31293549 A.32727947 A.50216726 AUTL O.00048394 O.00573636 O.21612337 O.37399203 http://www.streetinsider.com/Press+Releases/Autolus+Therapeutics+to+Present+Clinical+Data+Update+at+the+American+Society+of+Clinical+Oncology+Annual+Meeting+2026/26536774.html <p align="justify">LONDON and GAITHERSBURG, Md., May 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, announces the online publication of an abstract submitted to the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago, Illinois.</p> <p align="justify">“Data to be presented at the upcoming ASCO Annual Meeting provides insight into the use of obe-cel in patients with B-ALL and extramedullary disease (EMD), which is typically associated with shorter median and long-term survival http://www.streetinsider.com/Press+Releases/Autolus+Therapeutics+to+Present+Clinical+Data+Update+at+the+American+Society+of+Clinical+Oncology+Annual+Meeting+2026/26536774.html Thu, 21 May 2026 17:10:00 -0400 A.31293549 A.32727947 A.50216726 AUTL O.00048394 O.00573636 O.21612337 O.37399203 http://www.streetinsider.com/Press+Releases/Autolus+Therapeutics+to+Present+Clinical+Data+Update+at+the+American+Society+of+Clinical+Oncology+Annual+Meeting+2026/26536774.html <p align="justify">LONDON and GAITHERSBURG, Md., May 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, announces the online publication of an abstract submitted to the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago, Illinois.</p> <p align="justify">“Data to be presented at the upcoming ASCO Annual Meeting provides insight into the use of obe-cel in patients with B-ALL and extramedullary disease (EMD), which is typically associated with shorter median and long-term survival http://www.streetinsider.com/Press+Releases/Autolus+Therapeutics+to+Present+Clinical+Data+Update+at+the+American+Society+of+Clinical+Oncology+Annual+Meeting+2026/26536774.html Thu, 21 May 2026 17:10:00 -0400 A.31293549 A.32727947 A.50216726 AUTL O.00048394 O.00573636 O.21612337 O.37399203 http://www.streetinsider.com/Press+Releases/Autolus+Therapeutics+to+Present+Clinical+Data+Update+at+the+American+Society+of+Clinical+Oncology+Annual+Meeting+2026/26536774.html <p align="justify">LONDON and GAITHERSBURG, Md., May 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, announces the online publication of an abstract submitted to the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago, Illinois.</p> <p align="justify">“Data to be presented at the upcoming ASCO Annual Meeting provides insight into the use of obe-cel in patients with B-ALL and extramedullary disease (EMD), which is typically associated with shorter median and long-term survival http://www.streetinsider.com/Press+Releases/Autolus+Therapeutics+to+Present+Clinical+Data+Update+at+the+American+Society+of+Clinical+Oncology+Annual+Meeting+2026/26536774.html Thu, 21 May 2026 17:10:00 -0400 A.31293549 A.32727947 A.50216726 AUTL O.00048394 O.00573636 O.21612337 O.37399203 http://www.streetinsider.com/Press+Releases/Autolus+Therapeutics+to+Present+Clinical+Data+Update+at+the+American+Society+of+Clinical+Oncology+Annual+Meeting+2026/26536774.html <p align="justify">LONDON and GAITHERSBURG, Md., May 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, announces the online publication of an abstract submitted to the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago, Illinois.</p> <p align="justify">“Data to be presented at the upcoming ASCO Annual Meeting provides insight into the use of obe-cel in patients with B-ALL and extramedullary disease (EMD), which is typically associated with shorter median and long-term survival http://www.streetinsider.com/Press+Releases/Autolus+Therapeutics+to+Present+Clinical+Data+Update+at+the+American+Society+of+Clinical+Oncology+Annual+Meeting+2026/26536774.html Thu, 21 May 2026 17:10:00 -0400 A.31293549 A.32727947 A.50216726 AUTL O.00048394 O.00573636 O.21612337 O.37399203 http://www.streetinsider.com/Press+Releases/Autolus+Therapeutics+to+Present+Clinical+Data+Update+at+the+American+Society+of+Clinical+Oncology+Annual+Meeting+2026/26536774.html <p align="justify">LONDON and GAITHERSBURG, Md., May 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, announces the online publication of an abstract submitted to the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago, Illinois.</p> <p align="justify">“Data to be presented at the upcoming ASCO Annual Meeting provides insight into the use of obe-cel in patients with B-ALL and extramedullary disease (EMD), which is typically associated with shorter median and long-term survival http://www.streetinsider.com/Press+Releases/Autolus+Therapeutics+to+Present+Clinical+Data+Update+at+the+American+Society+of+Clinical+Oncology+Annual+Meeting+2026/26536774.html Thu, 21 May 2026 17:10:00 -0400 A.31293549 A.32727947 A.50216726 AUTL O.00048394 O.00573636 O.21612337 O.37399203 http://www.streetinsider.com/Globe+Newswire/Autolus+Therapeutics+to+Present+Clinical+Data+Update+at+the+American+Society+of+Clinical+Oncology+Annual+Meeting+2026/26536774.html <p align="justify">LONDON and GAITHERSBURG, Md., May 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, announces the online publication of an abstract submitted to the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago, Illinois.</p> <p align="justify">“Data to be presented at the upcoming ASCO Annual Meeting provides insight into the use of obe-cel in patients with B-ALL and extramedullary disease (EMD), which is typically associated with shorter median and long-term survival http://www.streetinsider.com/Globe+Newswire/Autolus+Therapeutics+to+Present+Clinical+Data+Update+at+the+American+Society+of+Clinical+Oncology+Annual+Meeting+2026/26536774.html Thu, 21 May 2026 17:10:00 -0400 A.31293549 A.32727947 A.50216726 AUTL O.00048394 O.00573636 O.21612337 O.37399203 http://www.streetinsider.com/Globe+Newswire/Autolus+Therapeutics+to+Present+Clinical+Data+Update+at+the+American+Society+of+Clinical+Oncology+Annual+Meeting+2026/26536774.html <p align="justify">LONDON and GAITHERSBURG, Md., May 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, announces the online publication of an abstract submitted to the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago, Illinois.</p> <p align="justify">“Data to be presented at the upcoming ASCO Annual Meeting provides insight into the use of obe-cel in patients with B-ALL and extramedullary disease (EMD), which is typically associated with shorter median and long-term survival http://www.streetinsider.com/Globe+Newswire/Autolus+Therapeutics+to+Present+Clinical+Data+Update+at+the+American+Society+of+Clinical+Oncology+Annual+Meeting+2026/26536774.html Thu, 21 May 2026 17:10:00 -0400 A.31293549 A.32727947 A.50216726 AUTL O.00048394 O.00573636 O.21612337 O.37399203 http://www.streetinsider.com/Globe+Newswire/Autolus+Therapeutics+to+Present+Clinical+Data+Update+at+the+American+Society+of+Clinical+Oncology+Annual+Meeting+2026/26536774.html <p align="justify">LONDON and GAITHERSBURG, Md., May 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, announces the online publication of an abstract submitted to the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago, Illinois.</p> <p align="justify">“Data to be presented at the upcoming ASCO Annual Meeting provides insight into the use of obe-cel in patients with B-ALL and extramedullary disease (EMD), which is typically associated with shorter median and long-term survival http://www.streetinsider.com/Globe+Newswire/Autolus+Therapeutics+to+Present+Clinical+Data+Update+at+the+American+Society+of+Clinical+Oncology+Annual+Meeting+2026/26536774.html Thu, 21 May 2026 17:10:00 -0400 A.31293549 A.32727947 A.50216726 AUTL O.00048394 O.00573636 O.21612337 O.37399203 http://www.streetinsider.com/Globe+Newswire/Autolus+Therapeutics+to+Present+Clinical+Data+Update+at+the+American+Society+of+Clinical+Oncology+Annual+Meeting+2026/26536774.html <p align="justify">LONDON and GAITHERSBURG, Md., May 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, announces the online publication of an abstract submitted to the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago, Illinois.</p> <p align="justify">“Data to be presented at the upcoming ASCO Annual Meeting provides insight into the use of obe-cel in patients with B-ALL and extramedullary disease (EMD), which is typically associated with shorter median and long-term survival http://www.streetinsider.com/Globe+Newswire/Autolus+Therapeutics+to+Present+Clinical+Data+Update+at+the+American+Society+of+Clinical+Oncology+Annual+Meeting+2026/26536774.html Thu, 21 May 2026 17:10:00 -0400 A.31293549 A.32727947 A.50216726 AUTL O.00048394 O.00573636 O.21612337 O.37399203 http://www.streetinsider.com/Globe+Newswire/Autolus+Therapeutics+to+Present+Clinical+Data+Update+at+the+American+Society+of+Clinical+Oncology+Annual+Meeting+2026/26536774.html <p align="justify">LONDON and GAITHERSBURG, Md., May 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, announces the online publication of an abstract submitted to the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago, Illinois.</p> <p align="justify">“Data to be presented at the upcoming ASCO Annual Meeting provides insight into the use of obe-cel in patients with B-ALL and extramedullary disease (EMD), which is typically associated with shorter median and long-term survival http://www.streetinsider.com/Globe+Newswire/Autolus+Therapeutics+to+Present+Clinical+Data+Update+at+the+American+Society+of+Clinical+Oncology+Annual+Meeting+2026/26536774.html Thu, 21 May 2026 17:10:00 -0400 A.31293549 A.32727947 A.50216726 AUTL O.00048394 O.00573636 O.21612337 O.37399203 http://www.streetinsider.com/Globe+Newswire/Autolus+Therapeutics+to+Present+Clinical+Data+Update+at+the+American+Society+of+Clinical+Oncology+Annual+Meeting+2026/26536774.html <p align="justify">LONDON and GAITHERSBURG, Md., May 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, announces the online publication of an abstract submitted to the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago, Illinois.</p> <p align="justify">“Data to be presented at the upcoming ASCO Annual Meeting provides insight into the use of obe-cel in patients with B-ALL and extramedullary disease (EMD), which is typically associated with shorter median and long-term survival http://www.streetinsider.com/Globe+Newswire/Autolus+Therapeutics+to+Present+Clinical+Data+Update+at+the+American+Society+of+Clinical+Oncology+Annual+Meeting+2026/26536774.html Thu, 21 May 2026 17:10:00 -0400 A.31293549 A.32727947 A.50216726 AUTL O.00048394 O.00573636 O.21612337 O.37399203 http://www.streetinsider.com/Globe+Newswire/Autolus+Therapeutics+to+Present+Clinical+Data+Update+at+the+American+Society+of+Clinical+Oncology+Annual+Meeting+2026/26536774.html <p align="justify">LONDON and GAITHERSBURG, Md., May 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, announces the online publication of an abstract submitted to the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago, Illinois.</p> <p align="justify">“Data to be presented at the upcoming ASCO Annual Meeting provides insight into the use of obe-cel in patients with B-ALL and extramedullary disease (EMD), which is typically associated with shorter median and long-term survival http://www.streetinsider.com/Globe+Newswire/Autolus+Therapeutics+to+Present+Clinical+Data+Update+at+the+American+Society+of+Clinical+Oncology+Annual+Meeting+2026/26536774.html Thu, 21 May 2026 17:10:00 -0400 A.31293549 A.32727947 A.50216726 AUTL O.00048394 O.00573636 O.21612337 O.37399203